← Leaderboards
Michael G Agadjanyan
Institute For Molecular Medicine
$30,814,858
Attributed
$48,629,748
Total exposure
10
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $9.4M · FY2008–25$10M$7.5M$5M$2.5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$48,629,748 · 10
By mechanism
R01$26,118,692 · 6
U01$19,170,731 · 3
RF1$3,340,325 · 1
Top collaborators
- David Hastings Cribbs17 shared
- Lon S Schneider6 shared
- David Sultzer5 shared
- James E Galvin3 shared
- Duygu Tosun-Turgut1 shared
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseaseVaccinesAntibodiesPathologyVaccinationAmyloid Beta-ProteinSafetyImmunizationMouse ModelVaccinatedImmunogenicBaseImpaired CognitionImmunogenicityEpitopesTau ProteinsB-Lymphocyte EpitopesClinical TrialsResponseBrainCellsPeptidesMemory
Grant awards (50)
FDA approved IND 29644: Multicenter Phase 1 Trial to Evaluate Safety and Immunogenicity of Preventive Tau Vaccine, AV-1980R/A, in cognitively unimpaired preclinical AD participants.$5,308,961
R01 · FY2025 · AG · contact PI
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.$2,288,273
R01 · FY2025 · AG · contact PI
IND enabling CMC/safety/toxicology studies, submission of IND and pilot Phase 1 clinical trial with PV-1950R vaccine for Lewy Body Dementia (LBD)$1,849,047
U01 · FY2025 · AG · contact PI
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.$2,243,861
R01 · FY2024 · AG · contact PI
IND enabling CMC/safety/toxicology studies, submission of IND and pilot Phase 1 clinical trial with PV-1950R vaccine for Lewy Body Dementia (LBD)$1,791,614
U01 · FY2024 · AG · contact PI
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.$2,408,617
R01 · FY2023 · AG · contact PI
Manufacturing of Drug Product, Dual Aβ/tau Vaccine for Clinical Trials$2,270,000
U01 · FY2023 · AG · contact PI
Manufacturing of New Batch AV-1959D Drug Product and Placebo for Phase 1 Trial$699,000
R01 · FY2023 · AG · contact PI
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.$2,680,709
R01 · FY2022 · AG · contact PI
IND-enabling Preclinical Studies on Anti-Tau AD Vaccine for Phase 1 Trial$2,237,972
U01 · FY2022 · AG · contact PI
Cooperative program U01 AG060965 Supplement: "Preparation of IND for Dual Aβ/Tau AD Vaccine for submission to FDA"$297,719
U01 · FY2022 · AG · contact PI
IND-enabling Preclinical Studies on Anti-Tau AD Vaccine for Phase 1 Trial$1,672,856
U01 · FY2021 · AG · contact PI
IND-enabling Preclinical Studies for Aβ and Dual Aβ/Tau MultiTEP platform-based AD Vaccines$1,346,072
U01 · FY2021 · AG · contact PI
Evaluation of Safe and Immunogenic Dose of AD Vaccine in aged non-human primates: Prelude to Phase 1 Preventive Vaccinations$419,490
U01 · FY2021 · AG · contact PI
IND-enabling Preclinical Studies on Anti-Tau AD Vaccine for Phase 1 Trial$1,272,333
U01 · FY2020 · AG · contact PI
Repurposing of Universal and Immunogenic MultiTEP Platform Designed for AD to Develop SARS-CoV-2 Multiepitope Vaccine$389,064
U01 · FY2020 · AG · contact PI
IND-enabling Preclinical Studies on Anti-Tau AD Vaccine for Phase 1 Trial$1,116,260
U01 · FY2019 · AG · contact PI
Multiple Approaches to Abeta Vaccination in Animal Models$3,340,325
RF1 · FY2018 · AG · contact PI
Pre-clinical study to fulfill FDA requirements for the completion of AV-1959 IND$927,669
U01 · FY2018 · AG · contact PI
Combining AD Epitope Vaccine with Innate Immunity$616,130
R01 · FY2018 · NS · contact PI
Pre-clinical study to fulfill FDA requirements for the completion of AV-1959 IND$1,253,815
U01 · FY2017 · AG · contact PI
Combining AD Epitope Vaccine with Innate Immunity$615,802
R01 · FY2017 · NS · contact PI
Combining AD Epitope Vaccine with Innate Immunity$10,210
R01 · FY2017 · NS · contact PI
Pre-clinical study to fulfill FDA requirements for the completion of AV-1959 IND$1,174,622
U01 · FY2016 · AG · contact PI
Combining AD Epitope Vaccine with Innate Immunity$617,150
R01 · FY2016 · NS · contact PI
Multiple Approaches to Abeta Vaccination in Animal Models$334,765
R01 · FY2016 · AG
Pre-clinical study to fulfill FDA requirements for the completion of AV-1959 IND$1,152,198
U01 · FY2015 · AG · contact PI
Combining AD Epitope Vaccine with Innate Immunity$622,995
R01 · FY2015 · NS · contact PI
Multiple Approaches to Abeta Vaccination in Animal Models$324,721
R01 · FY2015 · AG
Combining AD Epitope Vaccine with Innate Immunity$646,763
R01 · FY2014 · NS · contact PI
Multiple Approaches to Abeta Vaccination in Animal Models$334,765
R01 · FY2014 · AG
Combining AD Epitope Vaccine with Innate Immunity$404,429
R01 · FY2013 · NS
Multiple Approaches to Abeta Vaccination in Animal Models$315,772
R01 · FY2013 · AG
Combining AD Epitope Vaccine with Innate Immunity$433,515
R01 · FY2012 · NS
Immunogenicity & efficacy of chimeric flu virus expressing Ab42 B cell epitope$373,999
R01 · FY2012 · NS · contact PI
Multiple Approaches to Abeta Vaccination in Animal Models$335,943
R01 · FY2012 · AG
Combining AD Epitope Vaccine with Innate Immunity$446,424
R01 · FY2011 · NS
Immunogenicity & efficacy of chimeric flu virus expressing Ab42 B cell epitope$373,999
R01 · FY2011 · NS · contact PI
Combining AD Epitope Vaccine with Innate Immunity$442,458
R01 · FY2010 · NS
Immunogenicity & efficacy of chimeric flu virus expressing Ab42 B cell epitope$377,814
R01 · FY2010 · NS · contact PI
Combining AD Epitope Vaccine with Innate Immunity$422,898
R01 · FY2009 · NS
Immunogenicity & efficacy of chimeric flu virus expressing Ab42 B cell epitope$381,631
R01 · FY2009 · NS · contact PI
Immunogenicity & efficacy of chimeric flu virus expressing Ab42 B cell epitope$99,675
R01 · FY2009 · NS · contact PI
Immunogenicity & efficacy of chimeric flu virus expressing Ab42 B cell epitope$381,631
R01 · FY2008 · NS · contact PI
MECHANISM OF DIFFERENTIATION OF FUNCTION OF CD80 &CD86$334,790
R01 · FY2004 · AI
MECHANISM OF DIFFERENTIATION OF FUNCTION OF CD80 &CD86$325,038
R01 · FY2003 · AI
MECHANISM OF DIFFERENTIATION OF FUNCTION OF CD80 &CD86$315,570
R01 · FY2002 · AI
MECHANISM OF DIFFERENTIATION OF FUNCTION OF CD80 &CD86$306,379
R01 · FY2001 · AI
MECHANISM OF DIFFERENTIATION OF FUNCTION OF CD80 &CD86$261,251
R01 · FY2000 · AI
MECHANISM OF DIFFERENTIATION OF FUNCTION OF CD80 &CD86$32,754
R01 · FY2000 · AI